medigraphic.com
Centro de Investigaciones Regionales Dr. Hideyo Noguchi, Universidad Autónoma de Yucatán

2023, Number 3

<< Back Next >>

Rev Biomed 2023; 34 (3)

Antimicrobial resistance, the other side of the SARS-CoV-2 pandemic

Méndez-Elizalde CA, Arteaga-Tlecuitl R

Language: Spanish
References: 31
Page: 306-316
PDF size: 228.65 Kb.


ABSTRACT

With the emergence of SARS-CoV-2, we have another dimension in the study of bacterial resistance to antibiotics. The overuse of antibiotics, which has become more evident due to COVID-19, has been postulated as one of the riskiest practices in medical practice. The objective of the present work is to show the excessive use of antibiotics caused by the COVID-19 pandemic and its possible repercussion in the increased resistance to antibiotics by different bacterial groups. A systematic and descriptive literature review was conducted using various search engines such as PubMed, ScienceDirect, Medscape and SciELO, among others, over a 5-year timeline (2018-2022). Emphasis was placed on the bacterial groups and antibiotic families implicated in the suspected antimicrobial resistance generated during the pandemic and those that did not meet these characteristics were excluded. A comparison of the percentages of resistance to various antibiotics by priority bacterial groups suggests an increase, in some cases, nearly double, in resistance to some antibiotics; probably generated by the incorrect use of antibiotics during the pandemic. Although the algorithms for the treatment of COVID-19 established in international guidelines clearly establish the avoidance of using antibiotics as a first-line treatment, there are still medical personnel who prescribe antibiotics as first-line treatment, which has probably contributed to the development of antimicrobial resistance.


REFERENCES

  1. Larsson DG, Flach CF. Antibiotic resistance in theenvironment. Nat Rev Microbiol. 2022 May;20(5):257-269. doi: 10.1038/s41579-021-00649-x.

  2. Alcock BP, Raphenya AR, Lau TT, Tsang KK, BouchardM, Edalatmand A. et al. CARD 2020: antibioticresistome surveillance with the comprehensive antibioticresistance database. Nucleic Acids Res. 2020 Jan8;48(D1):D517-D525. doi: 10.1093/nar/gkz935.

  3. Huemer M, Mairpady Shambat S, Brugger SD,Zinkernagel AS. Antibiotic resistance and persistence-Implications for human health and treatment perspectives.EMBO Rep. 2020 Dec 3;21(12):e51034. doi: 10.15252/embr.202051034.

  4. Jorge P, Magalhães AP, Grainha T, Alves D, SousaAM, Lopes SP, et al. Antimicrobial resistance threeways: healthcare crisis, major concepts and therelevance of biofilms. FEMS Microbiol Ecol. 2019 Aug1;95(8):fiz115. doi: 10.1093/femsec/fiz115.

  5. Aslam B, Wang W, Arshad MI, Khurshid M, MuzammilS, Rasool MH, et al. Antibiotic resistance: a rundown ofa global crisis. Infect Drug Resist. 2018 Oct 10;11:1645-1658. doi: 10.2147/IDR.S173867.

  6. Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARSCoV-2 and COVID-19. Nat Rev Microbiol. 2021Mar;19(3):141-154. doi: 10.1038/s41579-020-00459-7.

  7. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, x Clinicalcourse and risk factors for mortality of adult inpatientswith COVID-19 in Wuhan, China: a retrospective cohortstudy. Lancet. 2020 Mar 28;395(10229):1054-1062. doi:10.1016/S0140-6736(20)30566-3.

  8. Li J, Wang J, Yang Y, Cai P, Cao J, Cai X, et al. Etiologyand antimicrobial resistance of secondary bacterialinfections in patients hospitalized with COVID-19 inWuhan, China: a retrospective analysis. AntimicrobResist Infect Control. 2020 Sep 22;9(1):153. doi:10.1186/s13756-020-00819-1.

  9. OPS. El preocupante impacto de la pandemia de laCOVID-19 en la resistencia antimicrobiana [Internet].Paho.org. 2021 [citado el 16 de septiembre de 2022].Disponible en: https://www.paho.org/es/noticias/22-11-2021-preocupante-impacto-pandemia-covid-19-resistencia-antimicrobiana

  10. Mahmoudi H. Bacterial co-infections and antibioticresistance in patients with COVID-19. GMS HygInfect Control. 2020 Dec 17;15:Doc35. doi: 10.3205/dgkh000370.

  11. López-Jácome LE, Fernández-Rodríguez D, Franco-Cendejas R, Camacho-Ortiz A, Morfin-Otero MDR,Rodríguez-Noriega E, et al. Increment AntimicrobialResistance During the COVID-19 Pandemic: Resultsfrom the Invifar Network. Microb Drug Resist. 2022Mar;28(3):338-345. doi: 10.1089/mdr.2021.0231.

  12. PérezMartínez CA, Padilla-Santamaría F, Helguera-León SA, Mejía-Cornejo JJ, Casados-RodríguezBE, Martínez-Abarca CI, et al. Uso y abuso deantimicrobianos en COVID-19: ¿cuándo está justificadoprescribir antibióticos? Med Int Méx. 2021; 37 (6):1015-1029.

  13. Rawson TM, Moore LSP, Castro-Sanchez E, Charani E,Davies F, Satta G, et al. COVID-19 and the potential longterm impact on antimicrobial resistance. J AntimicrobChemother. 2020 Jul 1;75(7):1681-1684. doi: 10.1093/jac/dkaa194.

  14. Lai CC, Chen SY, Ko WC, Hsueh PR. Increasedantimicrobial resistance during the COVID-19 pandemic.Int J Antimicrob Agents. 2021 Apr;57(4):106324. doi:10.1016/j.ijantimicag.2021.106324.

  15. Sosa GJO. Atención de pacientes con COVID-19 en elconsultorio médico. Rev CONAMED. 2020;25(Suppl:1):4-14. doi:10.35366/97343.

  16. Bárcena A, F Etienne C. Inicio [Internet]. La prolongaciónde la crisis sanitaria y su impacto en la salud, la economíay el desarrollo social; 14 de octubre de 2021 [consultadoel 16 de septiembre de 2022]. Disponible en: https://repositorio.cepal.org/bitstream/handle/11362/47301/1/S2100594_es.pdf

  17. Musuuza JS, Watson L, Parmasad V, Putman-BuehlerN, Christensen L, Safdar N. Prevalence and outcomes ofco-infection and superinfection with SARS-CoV-2 andother pathogens: A systematic review and meta-analysis.PLoS One. 2021 May 6;16(5):e0251170. doi: 10.1371/journal.pone.0251170.

  18. Langford BJ, So M, Raybardhan S, Leung V, WestwoodD, MacFadden DR, et al. Bacterial co-infection andsecondary infection in patients with COVID-19: aliving rapid review and meta-analysis. Clin MicrobiolInfect. 2020 Dec;26(12):1622-1629. doi: 10.1016/j.cmi.2020.07.016.

  19. Wan S, Xiang Y, Fang W, Zheng Y, Li B, Hu Y, et al.Clinical features and treatment of COVID-19 patients innortheast Chongqing. J Med Virol. 2020 Jul;92(7):797-806. doi: 10.1002/jmv.25783.

  20. Cox MJ, Loman N, Bogaert D, O’Grady J. Co-infections:potentially lethal and unexplored in COVID-19. LancetMicrobe. 2020 May;1(1):e11. doi: 10.1016/S2666-5247(20)30009-4.

  21. Spigaglia P. COVID-19 and Clostridioides difficileinfection (CDI): Possible implications for elderlypatients. Anaerobe. 2020 Aug;64:102233. doi: 10.1016/j.anaerobe.2020.102233.

  22. Contou D, Claudinon A, Pajot O, Micaëlo M, LonguetFlandre P, Dubert M, et al. Bacterial and viral coinfectionsin patients with severe SARS-CoV-2pneumonia admitted to a French ICU. Ann IntensiveCare. 2020 Sep 7;10(1):119. doi: 10.1186/s13613-020-00736-x.

  23. Al-Hadidi SH, Alhussain H, Abdel Hadi H, JoharA, Yassine HM, Al Thani AA, et al. The Spectrum ofAntibiotic Prescribing During COVID-19 Pandemic: ASystematic Literature Review. Microb Drug Resist. 2021Dec;27(12):1705-1725. doi: 10.1089/mdr.2020.0619.

  24. Organización Mundial de la Salud. OMS [Internet].Manejo clínico de la COVID-19; 25 de enero de2021 [consultado el 16 de septiembre de 2022].Disponible en: https://apps.who.int/iris/bitstream/handle/10665/340629/WHO-2019-nCoV-clinical-2021.1-spa.pdf

  25. Habboush Y, Guzman N. Antibiotic Resistance. 2022Jun 23. In: StatPearls [Internet]. Treasure Island (FL):StatPearls Publishing; 2023 Jan–.

  26. Antimicrobial Resistance Collaborators. Global burdenof bacterial antimicrobial resistance in 2019: a systematicanalysis. Lancet. 2022 Feb 12;399(10325):629-655. doi:10.1016/S0140-6736(21)02724-0.

  27. Garza-González E, Morfín-Otero R, Mendoza-OlazaránS, Bocanegra-Ibarias P, Flores-Treviño S, Rodríguez-Noriega E, et al. A snapshot of antimicrobial resistancein Mexico. Results from 47 centers from 20 statesduring a six-month period. PLoS One. 2019 Mar26;14(3):e0209865. doi: 10.1371/journal.pone.0209865.

  28. Berhe DF, Beyene GT, Seyoum B, Gebre M, Haile K,Tsegaye M, et al. Prevalence of antimicrobial resistanceand its clinical implications in Ethiopia: a systematicreview. Antimicrob Resist Infect Control. 2021 Dec3;10(1):168. doi: 10.1186/s13756-021-00965-0.

  29. Muhie OA. Antibiotic Use and Resistance Patternin Ethiopia: Systematic Review and Meta-Analysis.Int J Microbiol. 2019 Aug 1;2019:2489063. doi:10.1155/2019/2489063.

  30. Sharifipour E, Shams S, Esmkhani M, et al. Evaluationof bacterial co-infections of the respiratory tract inCOVID-19 patients admitted to ICU. BMC InfectDis. 2020 Sep 1;20(1):646. doi: 10.1186/s12879-020-05374-z.

  31. Bahçe YG, Acer Ö, Özüdoğru O. Evaluation of bacterialagents isolated from endotracheal aspirate culturesof Covid-19 general intensive care patients and theirantibiotic resistance profiles compared to pre-pandemicconditions. Microb Pathog. 2022 Mar;164:105409. doi:10.1016/j.micpath.2022.105409.




2020     |     www.medigraphic.com